Investment Analysts’ Recent Ratings Updates for RxSight (RXST)

Several analysts have recently updated their ratings and price targets for RxSight (NASDAQ: RXST):

• 2/26/2025 – RxSight had its price target lowered by analysts at JPMorgan Chase & Co. from $62.00 to $40.00. They now have an “overweight” rating on the stock.
• 2/26/2025 – RxSight had its price target lowered by analysts at Stifel Nicolaus from $35.00 to $33.00. They now have a “hold” rating on the stock.
• 2/26/2025 – RxSight had its price target lowered by analysts at Wells Fargo & Company from $40.00 to $35.00. They now have an “equal weight” rating on the stock.
• 2/26/2025 – RxSight had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $43.00 price target on the stock.
• 1/13/2025 – RxSight had its price target lowered by analysts at Stifel Nicolaus from $40.00 to $35.00. They now have a “hold” rating on the stock.
• 1/13/2025 – RxSight had its price target lowered by analysts at Wells Fargo & Company from $42.00 to $40.00. They now have an “equal weight” rating on the stock.
• 1/13/2025 – RxSight had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.

RxSight Stock Performance

NASDAQ:RXST opened at $25.22 on Friday. RxSight, Inc. has a 1 year low of $24.64 and a 1 year high of $66.54. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -30.39 and a beta of 1.22. The business has a fifty day moving average of $30.76 and a 200-day moving average of $41.40.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The business had revenue of $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. On average, equities research analysts predict that RxSight, Inc. will post -0.7 EPS for the current year.

Insider Activity

In other news, Director Shweta Maniar sold 3,519 shares of the company’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $30.87, for a total value of $108,631.53. Following the completion of the sale, the director now owns 7,383 shares in the company, valued at $227,913.21. This represents a 32.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Jesse Anderson Corley acquired 1,443 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was purchased at an average price of $31.18 per share, with a total value of $44,992.74. Following the acquisition, the director now owns 1,443 shares of the company’s stock, valued at approximately $44,992.74. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 9.36% of the company’s stock.

Institutional Investors Weigh In On RxSight

Several hedge funds have recently modified their holdings of the stock. Polar Asset Management Partners Inc. purchased a new stake in shares of RxSight during the fourth quarter valued at $1,606,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of RxSight by 23.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 84,958 shares of the company’s stock valued at $2,921,000 after purchasing an additional 16,140 shares during the last quarter. Voloridge Investment Management LLC lifted its holdings in shares of RxSight by 138.9% during the fourth quarter. Voloridge Investment Management LLC now owns 365,617 shares of the company’s stock valued at $12,570,000 after purchasing an additional 212,599 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in shares of RxSight by 12.5% during the fourth quarter. Squarepoint Ops LLC now owns 133,125 shares of the company’s stock valued at $4,577,000 after purchasing an additional 14,799 shares during the last quarter. Finally, Tidal Investments LLC purchased a new stake in shares of RxSight during the fourth quarter valued at $355,000. 78.78% of the stock is owned by hedge funds and other institutional investors.

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.